small molecule

ZURZUVAE

ZURANOLONE

Loss of exclusivityAugust 2037latest FDA-listed patent expiry
CompanyBiogenView the full company profile on CliffBio

Drug detail

Brand nameZURZUVAE
Active ingredientZURANOLONE
Strength30MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

Listed patents

PatentExpiresType
11884696August 2037use U-2552
11236121August 2037substance
10342810April 2034use U-2552
10172871April 2034use U-2552
9512165April 2034substance, product

Regulatory exclusivity

CodeExpires
NCEOctober 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZURZUVAE patent cliff — loss of exclusivity August 2037 | CliffBio